1. Characteristics

DW-1350 stimulates bone formation and inhibits bone resorption. It is now on the stage of clinical development for the treatment and prevention of osteoporosis.

2. Potential advantages

1) Small molecule

2) Stimulator of bone formation and inhibitor of bone resorption

3) Good efficacy (in animal models)

4) Good safety profile (in preclinical and clinical)

3. Status

1) Phase I

2) Co-development with Teijin Pharmaceuticals (Japan)